Palvella Therapeutics
PublicPalvella Therapeutics is now publicly traded
The data on this page reflects Palvella Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Dec 13, 2024
Est. Valuation at Exit
$195.3M
Total Funding Raised
$154.49M
Company Overview
Palvella Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with serious, rare genetic skin diseases.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Palvella Therapeutics Comparables
Compare Palvella Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PellePharm | 69% | |
| AiViva BioPharma | 56% | |
| Emtora Biosciences | 56% |
Palvella Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Dec 13, 2024 | ||||
| Grant | Oct 3, 2024 | ||||
| Series D | Jan 5, 2023 | ||||
| Series C | May 28, 2020 | ||||
| Series B | Aug 12, 2019 | ||||
Series A | Apr 12, 2019 |
Palvella Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gore Range Capital | Private Placement, Series D |
| Ligand Pharmaceuticals | Private Placement, Series C, Corporate Funding |
| Agent Capital | Series C, Series D |
| ADAR1 Capital Management | Private Placement |
| CAM Capital | Series C, Private Placement |
| Concord Biotech | Private Placement |
| Petrichor Healthcare Capital Management | Series D |
Palvella Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access